ArticleSalud publica de Mexico2024
Article in Salud publica de Mexico, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo evaluate the mortality rates of prostate cancer in Latin American and the Caribbean (LAC) countries and predict their mortality to 2030. MATERIALS AND
methodsThe data was retrieved from the World Health Organization mortality database. The age-standardized mortality rates for prostate cancer were estimated per 100 000 men between 1997 and 2017 for most LAC countries. The annual percent change was calculated by country and age group. The Nordpred was used to project prostate cancer mortality to 2030.
resultsFrom 1997 to 2017, the countries with the highest mortality rates from prostate cancer were Trinidad and Tobago, Cuba, and Venezuela. For all ages, ten LAC countries presented significant decreases between -0.5 and -2.8%, whereas Brazil, Cuba, Guatemala, and Venezuela showed increases. Mortality by prostate cancer will increase in 2030 due to changes in the structure and size of the population.
conclusionDespite the decline in prostate cancer mortality rates over the last two decades in most countries in the region, some countries still have very high mortality rates. By 2030, most countries in the region will show overall increases in the number of deaths, mainly due to population size.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.